- Home
- FTS vs RVMD Comparison
FTS vs RVMD Comparison
Compare FTS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTS | RVMD |
|---|---|---|
| Founded | 1885 | 2014 |
| Country | Canada | United States |
| Employees | 9900 | 883 |
| Industry | Electric Utilities: Central | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5B | 30.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FTS | RVMD |
|---|---|---|
| Price | $55.95 | $198.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $67.00 | ★ $140.84 |
| AVG Volume (30 Days) | 640.0K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.05 | N/A |
| Revenue Next Year | $5.32 | $533.02 |
| P/E Ratio | $22.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.69 | $34.15 |
| 52 Week High | $59.40 | $198.30 |
Technical Indicators
Market Signals| Indicator | FTS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 61.86 |
| Support Level | $55.93 | $177.04 |
| Resistance Level | $57.78 | N/A |
| Average True Range (ATR) | 0.80 | 7.37 |
| MACD | -0.25 | 0.23 |
| Stochastic Oscillator | 18.86 | 90.72 |
Price Performance
Historical ComparisonAbout FTS Fortis Inc.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.